4 assets in Cardiomyopathy Due To Anthracyclines

Therapeutic assets addressing Cardiomyopathy Due To Anthracyclines, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Rosuvastatin Cardiomyopathy Due To Anthracyclines	Shiraz University of Medical Sciences	P4	BB (65)
Dapagliflozin Cardiomyopathy Due To Anthracyclines	University Medical Centre Ljubljana	P2	CCC (53)
Sotagliflozin Cardiomyopathy Due To Anthracyclines	Icahn School of Medicine at Mount Sinai	P2	CCC (53)
Sfx-01 (Sulforaphane Stabilized With .Alpha. Cyclodextrin) Cardiomyopathy Due To Anthracyclines	Texas Tech University Health Sciences Center	P1/2	CCC (48)